首页> 外文期刊>Therapeutic Drug Monitoring >Barbiturate detection in oral fluid, plasma, and urine.
【24h】

Barbiturate detection in oral fluid, plasma, and urine.

机译:口服液,血浆和尿液中的巴比妥酸盐检测。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Although current abuse of barbiturates is low compared with other classes of abused drugs, their narrow margin of safety, risk of dependence, and abuse liability remain a health concern. Limited information is available on the disposition of barbiturates in different biologic matrices. OBJECTIVE: The authors conducted a clinical study of the disposition of barbiturates in oral fluid, plasma, and urine after single-dose administration to healthy subjects. METHODS: Three parallel groups of 15 subjects were administered a single oral dose of one barbiturate: butalbital (50 mg), Phenobarbital (30 mg), or sodium secobarbital (100 mg). Subjects remained at the clinic for two confinement periods; the first was -1 to 36 hours postdose and again at 48 to 52 hours. Oral fluid specimens were collected by bilateral collection (Intercept; one on each side of the mouth simultaneously). Blood specimens were obtained by venipuncture and urine specimens were collected through separate collection pools of varying periods. Oral fluid specimens were analyzed for barbiturates by liquid chromatography-tandem mass spectroscopy with a limit of quantitation of 8 ng/mL. Plasma and urine specimens were analyzed by gas chromatography-mass spectroscopy with a limit of quantitation of 100 ng/mL. RESULTS: Barbiturate side effects included dizziness, drowsiness, and somnolence. All effects resolved spontaneously without medical intervention. The three barbiturates were detectable in oral fluid and plasma within 15 to 60 minutes of administration and in the first urine pooled collection at 2 hours. Butalbital and Phenobarbital remained detectable in all specimens through 48 to 52 hours, whereas secobarbital was frequently negative in the last collection. Oral fluid to plasma ratios appeared stable over the 1- to 48-hour collection period. CONCLUSION: This study demonstrated that single, oral therapeutic doses of butalbital, Phenobarbital, and secobarbital were excreted in readily detectable concentrations in oral fluid over a period of approximately 2 days. Oral fluid patterns of appearance and elimination were similar to that observed for plasma and urine.
机译:背景:尽管与其他类别的滥用药物相比,当前的巴比妥类药物滥用率较低,但它们的安全范围窄,依赖风险和滥用责任仍然是健康问题。关于在不同生物基质中巴比妥酸盐的处置情况,提供的信息有限。目的:作者对健康受试者单剂量给药后巴比妥酸盐在口腔液,血浆和尿液中的分布进行了临床研究。方法:15名受试者的三个平行组被单次口服一种巴比妥酸盐:丁比妥(50 mg),苯巴比妥(30 mg)或司可巴比妥钠(100 mg)。受试者在诊所呆了两个月;首先是服药后-1至36小时,然后是48至52小时。通过双边采集(拦截;在口腔的每一侧同时采集)收集口腔液标本。通过静脉穿刺获得血液样本,并通过不同时期的单独收集池收集尿液样本。通过液相色谱-串联质谱法对口服液标本中的巴比妥类进行分析,定量限为8 ng / mL。通过气相色谱-质谱法分析血浆和尿液标本,定量限为100 ng / mL。结果:巴比妥类药物的副作用包括头晕,嗜睡和嗜睡。在没有医疗干预的情况下,所有影响都会自发解决。在给药后15至60分钟内以及口服尿液在2小时内收集到的第一批尿液中,在口服液和血浆中可检测到三种巴比妥酸盐。在所有标本中,在48至52小时内仍可检测到丁比妥和苯巴比妥,而上次采集的巴比妥和巴比妥通常为阴性。口服液与血浆的比例在1至48小时的收集期内似乎保持稳定。结论:这项研究表明,口服治疗剂量的丁比妥,苯巴比妥和司可巴比妥在大约2天的时间内就以易于检测的浓度排泄到口腔液中。口腔液的出现和消除方式与血浆和尿液相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号